FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912304448> ?p ?o ?g. }

• W2912304448 abstract "Abstract Background Ewing sarcoma (ES), a bone cancer affecting children, adolescents, and young adults, is driven by the EWS‐FLI1 fusion protein in the majority of cases, but the mechanisms of tumorigenesis are still being elucidated. Consequentially, therapeutic advances have been limited in the last 25 years. Two therapeutic targets have been recently examined. Aurora kinase A (AURKA) promotes cell cycling and posttranslational stabilization of the oncoprotein MYC, while bromodomain‐containing protein 4 (BRD4) promotes gene expression epigenetically. Studies of AURKA and BRD4 inhibitors showed some impairment of tumorigenesis in ES preclinical models, but this efficacy was limited in single‐agent use. AURKA and BRD4 activate common oncogenic pathways through different mechanisms, so we hypothesized dual inhibition would be synergistic against tumorigenesis. Aims (a) Define the synergistic antineoplastic effects of BRD4 inhibitor I‐BET151 and AURKA inhibitor alisertib against ES cell lines in vitro. (b) Confirm the mechanism of activity of each agent in these cell line models. (c) Define the efficacy of I‐BET 151 and alisertib alone and in combinations with each other, and with the chemotherapeutic drug vincristine against ES tumor xenografts in vivo. Methods and results I‐BET151 and alisertib synergistically inhibit viability in ES cell lines SK‐ES, TC71, and ES2 in vitro. Alisertib alone upregulates transcriptional expression of its targets, but combined use of I‐BET151 mitigates that upregulation, likely contributing to the drug synergy and downregulating RNA and protein expression of key oncogenic pathways as shown by RT‐qPCR and western blot. Alisertib and I‐BET151 significantly prolong survival in three ES xenograft models in vivo, and this efficacy is augmented by the addition of vincristine. Conclusion Dual targeting of oncogenic drivers in ES epigenetically and posttranslationally, specifically by use of BRD4 and AURKA inhibitors, may have significant clinical efficacy in ES alone and/or in combination with current chemotherapy regimens." @default.
• W2912304448 created "2019-02-21" @default.
• W2912304448 creator A5052898073 @default.
• W2912304448 creator A5056179686 @default.
• W2912304448 creator A5075343448 @default.
• W2912304448 creator A5083166471 @default.
• W2912304448 creator A5089758323 @default.
• W2912304448 date "2019-02-11" @default.
• W2912304448 modified "2023-10-16" @default.
• W2912304448 title "Combinatorial BRD4 and AURKA inhibition is synergistic against preclinical models of Ewing sarcoma" @default.
• W2912304448 cites W1846429449 @default.
• W2912304448 cites W1945032888 @default.
• W2912304448 cites W1951627305 @default.
• W2912304448 cites W1973578742 @default.
• W2912304448 cites W1974771871 @default.
• W2912304448 cites W1976672500 @default.
• W2912304448 cites W1984507712 @default.
• W2912304448 cites W1990317973 @default.
• W2912304448 cites W1992127633 @default.
• W2912304448 cites W1993186884 @default.
• W2912304448 cites W1994568630 @default.
• W2912304448 cites W1995557117 @default.
• W2912304448 cites W2007438323 @default.
• W2912304448 cites W2015511149 @default.
• W2912304448 cites W2025989401 @default.
• W2912304448 cites W2026853588 @default.
• W2912304448 cites W2029457245 @default.
• W2912304448 cites W2036463815 @default.
• W2912304448 cites W2036868427 @default.
• W2912304448 cites W2038619046 @default.
• W2912304448 cites W2044351445 @default.
• W2912304448 cites W2050780415 @default.
• W2912304448 cites W2052692973 @default.
• W2912304448 cites W2052787205 @default.
• W2912304448 cites W2057466968 @default.
• W2912304448 cites W2068073581 @default.
• W2912304448 cites W2069492488 @default.
• W2912304448 cites W2077212219 @default.
• W2912304448 cites W2077945404 @default.
• W2912304448 cites W2098640714 @default.
• W2912304448 cites W2108541596 @default.
• W2912304448 cites W2113462447 @default.
• W2912304448 cites W2114220172 @default.
• W2912304448 cites W2124328974 @default.
• W2912304448 cites W2128628566 @default.
• W2912304448 cites W2138805078 @default.
• W2912304448 cites W2146157298 @default.
• W2912304448 cites W2147440283 @default.
• W2912304448 cites W2151041593 @default.
• W2912304448 cites W2151526351 @default.
• W2912304448 cites W2151962695 @default.
• W2912304448 cites W2164937682 @default.
• W2912304448 cites W2169091268 @default.
• W2912304448 cites W2183670742 @default.
• W2912304448 cites W2269379690 @default.
• W2912304448 cites W2286870626 @default.
• W2912304448 cites W2298793032 @default.
• W2912304448 cites W2307422613 @default.
• W2912304448 cites W2373840880 @default.
• W2912304448 cites W2399797906 @default.
• W2912304448 cites W2412073247 @default.
• W2912304448 cites W2476685579 @default.
• W2912304448 cites W2513820391 @default.
• W2912304448 cites W2523041838 @default.
• W2912304448 cites W2530695968 @default.
• W2912304448 cites W2531661710 @default.
• W2912304448 cites W2545879467 @default.
• W2912304448 cites W2585819714 @default.
• W2912304448 cites W2589078946 @default.
• W2912304448 cites W2593764076 @default.
• W2912304448 cites W2750463384 @default.
• W2912304448 cites W2762036131 @default.
• W2912304448 cites W2792813139 @default.
• W2912304448 cites W2808609689 @default.
• W2912304448 cites W2811413097 @default.
• W2912304448 doi "https://doi.org/10.1002/cnr2.1163" @default.
• W2912304448 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7941462" @default.
• W2912304448 hasPublicationYear "2019" @default.
• W2912304448 type Work @default.
• W2912304448 sameAs 2912304448 @default.
• W2912304448 citedByCount "0" @default.
• W2912304448 crossrefType "journal-article" @default.
• W2912304448 hasAuthorship W2912304448A5052898073 @default.
• W2912304448 hasAuthorship W2912304448A5056179686 @default.
• W2912304448 hasAuthorship W2912304448A5075343448 @default.
• W2912304448 hasAuthorship W2912304448A5083166471 @default.
• W2912304448 hasAuthorship W2912304448A5089758323 @default.
• W2912304448 hasBestOaLocation W29123044482 @default.
• W2912304448 hasConcept C104317684 @default.
• W2912304448 hasConcept C105696609 @default.
• W2912304448 hasConcept C121608353 @default.
• W2912304448 hasConcept C127561419 @default.
• W2912304448 hasConcept C146276462 @default.
• W2912304448 hasConcept C185592680 @default.
• W2912304448 hasConcept C2779634854 @default.
• W2912304448 hasConcept C29537977 @default.
• W2912304448 hasConcept C41091548 @default.
• W2912304448 hasConcept C502942594 @default.
• W2912304448 hasConcept C54355233 @default.
• W2912304448 hasConcept C55493867 @default.

• next